A number like 100% doesn't appear in cancer research very often.
When it does, it commands attention.
A Phase 1 clinical trial of TG4050 — an individualised therapeutic cancer vaccine developed by French biotech Transgene, powered by AI from Japanese tech company NEC — has shown 100% disease-free survival at two years in patients treated for high-risk, HPV-negative head and neck squamous cell carcinoma.
Every patient who received the vaccine after completing primary treatment remained cancer-free at the two-year mark.
The data, published as a preprint on medRxiv in January 2026 and submitted for peer review, followed patients for a median of 30 months. The vaccine was given as a monotherapy in the adjuvant setting — meaning after surgery and other primary treatment — to prevent the cancer coming back.
'Adjuvant' treatment of this kind is one of the hardest problems in oncology. The tumour is gone, but the risk of recurrence is real and high. Traditional adjuvant chemotherapy and radiation can reduce that risk but carry significant toxicity. A personalised vaccine that trains the immune system to hunt and destroy residual tumour cells is a fundamentally different approach — and in this trial, it worked.
The science behind it is elegant. Each patient's tumour is analysed to identify its unique neoantigens — the specific mutations that make cancer cells distinguishable from healthy ones. NEC's AI platform then designs a personalised vaccine targeting those specific neoantigens. Transgene manufactures the vaccine individually for each patient. The result is a therapy that is, by design, bespoke.
Translational findings confirmed that TG4050 induced durable, neoantigen-specific T-cell responses — meaning the immune system was genuinely activated and learning — in 73% of evaluable patients. The vaccine was well-tolerated with no unexpected safety signals.
Phase II trials are underway, with initial immunogenicity data expected in the second half of 2026 and preliminary efficacy data in 2027.
Head and neck cancer is the seventh most common cancer worldwide. For HPV-negative cases — which are harder to treat and carry a higher recurrence risk — new options are desperately needed.
A vaccine that turns the immune system into a personalised assassin. A two-year result of 100%.
Some numbers do command attention. This one earned it. 💉